Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
David B Price,1,2 William Henley,1,3 José Eduardo Delfini Cançado,4 Leonardo M Fabbri,5 Huib AM Kerstjens,6 Alberto Papi,7 Nicolas Roche,8 Elif Şen,9 Dave Singh,10 Claus F Vogelmeier,11 Sara Barille,12 Elena Nudo,12 Victoria Carter,1 Derek Skinner,1 Rebecca Vella,1 George Georges13 1Obser...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-02-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/interclass-difference-in-pneumonia-risk-in-copd-patients-initiating-fi-peer-reviewed-fulltext-article-COPD |
| _version_ | 1819278829383843840 |
|---|---|
| author | Price DB Henley W Cançado JED Fabbri LM Kerstjens HA Papi A Roche N Şen E Singh D Vogelmeier CF Barille S Nudo E Carter V Skinner D Vella R Georges G |
| author_facet | Price DB Henley W Cançado JED Fabbri LM Kerstjens HA Papi A Roche N Şen E Singh D Vogelmeier CF Barille S Nudo E Carter V Skinner D Vella R Georges G |
| author_sort | Price DB |
| collection | DOAJ |
| description | David B Price,1,2 William Henley,1,3 José Eduardo Delfini Cançado,4 Leonardo M Fabbri,5 Huib AM Kerstjens,6 Alberto Papi,7 Nicolas Roche,8 Elif Şen,9 Dave Singh,10 Claus F Vogelmeier,11 Sara Barille,12 Elena Nudo,12 Victoria Carter,1 Derek Skinner,1 Rebecca Vella,1 George Georges13 1Observational and Pragmatic Research Institute, Singapore; 2Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 3Health Statistics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK; 4Santa Casa de São Paulo Medical School, São Paulo, Brazil; 5Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy; 6Department of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, and Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, Netherlands; 7Respiratory Medicine, University of Ferrara, Ferrara, Italy; 8Department of Respiratory Medicine, APHP-Centre University of Paris, Cochin Institute, Paris, France; 9Department of Pulmonary Medicine, Ankara University School of Medicine, Ankara, Turkey; 10Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 11Department of Internal Medicine, Pulmonary and Critical Care Medicine, University of Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany; 12Global Medical Affairs, Chiesi Farmaceutici, S.p.A., Parma, Italy; 13Global Clinical Development, Chiesi Farmaceutici, S.p.A., Parma, ItalyCorrespondence: David B Price, Observational and Pragmatic Research Institute, 22 Sin Ming Lane, #06-76, Midview City, 573969, Singapore, Email dprice@opri.sgBackground: Inhaled corticosteroids (ICS) afford therapeutic benefits in some COPD patients, but their widespread use is cautioned due to an increased risk of developing pneumonia. Subclass variations exist, and the risk profile differs for individual ICS. Formulation particle size has been identified as a potential effect modifier. The present study compared the risk of pneumonia among new COPD users of fixed-dose combination inhalers containing fine-particle fluticasone (fp-FDC-F) versus extrafine particle beclometasone (ef-FDC-BDP).Methods: A propensity matched historical cohort study was conducted using data from the Optimum Patient Care Research Database. COPD patients aged ≥ 40 years with ≥ 1 year of continuous medical data who initiated fp-FDC-F or ef-FDC-BDP were compared. The primary outcome was time to pneumonia event, as treated, using either sensitive (physician diagnosed) or specific (physician diagnosed and x-ray or hospital admission confirmed) definitions.Results: A total of 13,316 patients were matched. Initiation of fp-FDC-F (mean dosage furoate 99 μg; propionate 710 μg) was associated with an increased risk of pneumonia versus ef-FDC-BDP (mean beclometasone dose 395 μg), irrespective of definition (sensitive HR 1.38 95% CI 1.14– 1.68; specific HR 1.31 95% CI 1.05– 1.62).Conclusion: In the current investigation, we found that in comparison to extrafine beclomethasone, commencing a formulation containing fluticasone is associated with an increased risk of developing pneumonia. These observations support the idea that not all ICS are equal in their adverse effects and subclass variations exist and should be carefully considered in the treatment choice.Keywords: inhaled corticosteroids, pneumonia, COPD, extrafine beclomethasone, fluticasone |
| first_indexed | 2024-12-24T00:18:13Z |
| format | Article |
| id | doaj.art-8341bb0405f24a12bbc16bbf371d195c |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-12-24T00:18:13Z |
| publishDate | 2022-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-8341bb0405f24a12bbc16bbf371d195c2022-12-21T17:24:40ZengDove Medical PressInternational Journal of COPD1178-20052022-02-01Volume 1735537072911Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle FluticasonePrice DBHenley WCançado JEDFabbri LMKerstjens HAPapi ARoche NŞen ESingh DVogelmeier CFBarille SNudo ECarter VSkinner DVella RGeorges GDavid B Price,1,2 William Henley,1,3 José Eduardo Delfini Cançado,4 Leonardo M Fabbri,5 Huib AM Kerstjens,6 Alberto Papi,7 Nicolas Roche,8 Elif Şen,9 Dave Singh,10 Claus F Vogelmeier,11 Sara Barille,12 Elena Nudo,12 Victoria Carter,1 Derek Skinner,1 Rebecca Vella,1 George Georges13 1Observational and Pragmatic Research Institute, Singapore; 2Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 3Health Statistics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK; 4Santa Casa de São Paulo Medical School, São Paulo, Brazil; 5Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy; 6Department of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, and Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, Netherlands; 7Respiratory Medicine, University of Ferrara, Ferrara, Italy; 8Department of Respiratory Medicine, APHP-Centre University of Paris, Cochin Institute, Paris, France; 9Department of Pulmonary Medicine, Ankara University School of Medicine, Ankara, Turkey; 10Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 11Department of Internal Medicine, Pulmonary and Critical Care Medicine, University of Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany; 12Global Medical Affairs, Chiesi Farmaceutici, S.p.A., Parma, Italy; 13Global Clinical Development, Chiesi Farmaceutici, S.p.A., Parma, ItalyCorrespondence: David B Price, Observational and Pragmatic Research Institute, 22 Sin Ming Lane, #06-76, Midview City, 573969, Singapore, Email dprice@opri.sgBackground: Inhaled corticosteroids (ICS) afford therapeutic benefits in some COPD patients, but their widespread use is cautioned due to an increased risk of developing pneumonia. Subclass variations exist, and the risk profile differs for individual ICS. Formulation particle size has been identified as a potential effect modifier. The present study compared the risk of pneumonia among new COPD users of fixed-dose combination inhalers containing fine-particle fluticasone (fp-FDC-F) versus extrafine particle beclometasone (ef-FDC-BDP).Methods: A propensity matched historical cohort study was conducted using data from the Optimum Patient Care Research Database. COPD patients aged ≥ 40 years with ≥ 1 year of continuous medical data who initiated fp-FDC-F or ef-FDC-BDP were compared. The primary outcome was time to pneumonia event, as treated, using either sensitive (physician diagnosed) or specific (physician diagnosed and x-ray or hospital admission confirmed) definitions.Results: A total of 13,316 patients were matched. Initiation of fp-FDC-F (mean dosage furoate 99 μg; propionate 710 μg) was associated with an increased risk of pneumonia versus ef-FDC-BDP (mean beclometasone dose 395 μg), irrespective of definition (sensitive HR 1.38 95% CI 1.14– 1.68; specific HR 1.31 95% CI 1.05– 1.62).Conclusion: In the current investigation, we found that in comparison to extrafine beclomethasone, commencing a formulation containing fluticasone is associated with an increased risk of developing pneumonia. These observations support the idea that not all ICS are equal in their adverse effects and subclass variations exist and should be carefully considered in the treatment choice.Keywords: inhaled corticosteroids, pneumonia, COPD, extrafine beclomethasone, fluticasonehttps://www.dovepress.com/interclass-difference-in-pneumonia-risk-in-copd-patients-initiating-fi-peer-reviewed-fulltext-article-COPDinhaled corticosteroidspneumoniacopdextrafine beclomethasonefluticasone |
| spellingShingle | Price DB Henley W Cançado JED Fabbri LM Kerstjens HA Papi A Roche N Şen E Singh D Vogelmeier CF Barille S Nudo E Carter V Skinner D Vella R Georges G Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone International Journal of COPD inhaled corticosteroids pneumonia copd extrafine beclomethasone fluticasone |
| title | Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone |
| title_full | Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone |
| title_fullStr | Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone |
| title_full_unstemmed | Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone |
| title_short | Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone |
| title_sort | interclass difference in pneumonia risk in copd patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone |
| topic | inhaled corticosteroids pneumonia copd extrafine beclomethasone fluticasone |
| url | https://www.dovepress.com/interclass-difference-in-pneumonia-risk-in-copd-patients-initiating-fi-peer-reviewed-fulltext-article-COPD |
| work_keys_str_mv | AT pricedb interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT henleyw interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT cancadojed interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT fabbrilm interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT kerstjensha interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT papia interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT rochen interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT sene interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT singhd interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT vogelmeiercf interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT barilles interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT nudoe interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT carterv interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT skinnerd interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT vellar interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone AT georgesg interclassdifferenceinpneumoniariskincopdpatientsinitiatingfixeddoseinhaledtreatmentcontainingextrafineparticlebeclometasoneversusfineparticlefluticasone |